PMID- 31649806
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2008-3009 (Print)
IS  - 2008-2207 (Electronic)
IS  - 2008-2207 (Linking)
VI  - 13
IP  - 3
DP  - 2019 Jul 1
TI  - Dickkopf-1 and Amphiregulin as Novel Biomarkers and Potential Therapeutic Targets 
      in Hepatocellular Carcinoma.
PG  - 153-163
AB  - Background: Hepatocellular carcinoma (HCC) is a highly fatal tumor which 
      represents a major health problem worldwide. Due to asymptomatic nature of HCC, 
      most patients present with the progressive stage of disease, so, unfortunately, 
      there are no effective therapies. Existing techniques for HCC surveillance and 
      diagnosis lack the required accuracy. Therefore, searching for new diagnostic 
      and/or therapeutic tools could improve patient survival. This study aimed to 
      estimate the diagnostic role of Dickkopf-1 (DKK1) and amphiregulin (AREG) and to 
      find out their correlation with different clinicopathological parameters in HCC 
      patients. Materials and Methods: Serum levels of DKK1 and AREG in 55 HCC 
      patients, 20 cirrhotic patients, and 15 healthy subjects as control group were 
      measured using the ELISA technique. Results: Both of DKK1 and AREG showed a 
      significant increase in the HCC group compared to cirrhotic and healthy groups. 
      DKK1 at a cutoff point of 8.92 ng/ml showed that the area under the curve (AUC) 
      was 0.826 with 87.3% sensitivity and 82.9% specificity. DKK1 showed a significant 
      correlation with tumor size, liver dysfunction, and poor performance status in 
      HCC patients. AREG at a cutoff point of 8.74 pg/ml showed a sensitivity of 74.5% 
      but low specificity (47.1%). AREG showed a significant correlation with portal 
      vein thrombosis and tumor metastasis in HCC patients. Conclusion: Serum DKK1 
      could be a diagnostic biomarker for HCC. Both of DKK1 and AREG may play 
      significant roles in tumor progression and may offer promising therapeutic 
      targets in HCC patients.
CI  - Copyright : (c) International Journal of Hematology-Oncology and Stem Cell Research 
      & Tehran University of Medical Sciences.
FAU - Awad, Abeer E
AU  - Awad AE
AD  - Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 
      35516, Egypt.
FAU - Ebrahim, Mohamed A
AU  - Ebrahim MA
AD  - Oncology Centre, Faculty of Medicine, Mansoura University, Mansoura, 35516, 
      Egypt.
FAU - Eissa, Laila A
AU  - Eissa LA
AD  - Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 
      35516, Egypt.
FAU - El-Shishtawy, Mamdouh M
AU  - El-Shishtawy MM
AD  - Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 
      35516, Egypt.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Int J Hematol Oncol Stem Cell Res
JT  - International journal of hematology-oncology and stem cell research
JID - 101511150
PMC - PMC6801323
OTO - NOTNLM
OT  - Amphiregulin
OT  - Dickkopf-1
OT  - HCC
EDAT- 2019/10/28 06:00
MHDA- 2019/10/28 06:01
PMCR- 2019/07/01
CRDT- 2019/10/26 06:00
PHST- 2019/10/26 06:00 [entrez]
PHST- 2019/10/28 06:00 [pubmed]
PHST- 2019/10/28 06:01 [medline]
PHST- 2019/07/01 00:00 [pmc-release]
AID - IJHOSCR-13-153 [pii]
PST - ppublish
SO  - Int J Hematol Oncol Stem Cell Res. 2019 Jul 1;13(3):153-163.